I feel like I'm hitting this wall
Because retatrutide has no approved label, no established contraindications, warnings, monitoring requirements, or dosing instructions exist outside a trial one reason obtaining it outside research is unsafe
Brunchmann et al
The magnitude of the benefits of GLP-1RA and SGLT-2 inhibitors on MACE are similar in patients with T2D, ranging from 12 to 14% reduction of risk, but only GLP-1RA may reduce the risk of stroke (Fig
This is a normal, expected adjustment and not a reason to avoid GLP-1 therapy
States Offering Broad GLP-1 Coverage for Obesity A total of 14 states, including California, Michigan, and Pennsylvania, provide Medicaid coverage for the most common GLP-1s approved for both Type 2 diabetes and obesity